Edwards Lifesciences Corporation $EW Shares Sold by Guggenheim Capital LLC

by · The Markets Daily

Guggenheim Capital LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 2.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 194,182 shares of the medical research company’s stock after selling 5,877 shares during the quarter. Guggenheim Capital LLC’s holdings in Edwards Lifesciences were worth $15,187,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Edwards Lifesciences in the first quarter worth $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences in the 1st quarter worth about $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $28,000. Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $29,000. Finally, NewSquare Capital LLC raised its stake in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Wells Fargo & Company lifted their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. UBS Group restated a “neutral” rating on shares of Edwards Lifesciences in a research report on Wednesday. Mizuho upped their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Truist Financial raised their target price on Edwards Lifesciences from $87.00 to $90.00 and gave the company a “hold” rating in a research note on Monday, November 3rd. Finally, Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $91.52.

Get Our Latest Stock Report on Edwards Lifesciences

Edwards Lifesciences Trading Up 2.1%

Shares of EW stock opened at $85.72 on Friday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.40. The firm has a market capitalization of $49.74 billion, a PE ratio of 36.95, a price-to-earnings-growth ratio of 3.72 and a beta of 0.97. The stock has a fifty day moving average of $80.75 and a two-hundred day moving average of $78.68. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company’s revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Recommended Stories